Anlon Healthcare Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/70ngaynh2fudbidm9xlmchwl.pdf

Key Takeaways


Margin Dynamics

Punit Rasadia: "If things will be normal as per the pre-war situation, then we'll able to maintain the same EBITDA margin, otherwise it may impact on the EBITDA margin, but definitely we'll have the better pricing also in terms of the selling price."

Working Capital & Cash Flow

Punit Rasadia: "We have stopped the supply to them because we are the part of their drug master file for one of our KSM. So they cannot change the supplier immediately if I'll not supply to them, just on the basis of the payment terms and prices."

Capacity Expansion & Capex


CDMO & Product Pipeline


Competitive Position & Pricing Power

Punit Rasadia: "We have the always process upper hand in terms of specific chemistry like methylation and Friedel-Crafts where we have already cracked the chemistry and we have take out the cost of the manufacturing at certain level where we don't have means any competition."

Capital Allocation & Governance

Punit Rasadia: "CARE was doing the literally blackmailing to get the money and doing all that activity and finally we have not given them a single penny for withdrawing that rating, that's why they have published."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue₹380–400 croreFY27
Revenue₹700–800 croreFY28
Revenue CAGR~30% over three yearsFY26–FY28
EBITDA margin30–35% (standalone expectation on ₹380–400 Cr topline)FY27
EBITDA margin~25% consolidated (conservative, sustainable)FY27 and ongoing
PAT₹45 crore conservative, realistically ₹50–55 croreFY27
Cash flow from operationsPositive on annual basisFY27
Inventory reduction20–25% reductionBy Q2 FY27
Receivable daysAt least 180 days (below that impossible for API)FY27-end
New facility commissioningConstruction starts month-end; commercial productionQ1 FY28
New facility utilization50–60%FY28
CDMO first product commercial supplyCommercial supply beginsQ3 FY27
CDMO other two moleculesValidation completeQ2 FY27
CDMO other two moleculesCommercializationLast quarter FY27 or Q1 FY28
DMF commercialization5–7 products regularly commercialized for exportWithin FY27
Export contributionAt least 60% of revenueFY27
Capex funding₹65–70 Cr term loan (50–60% of capex), balance internal; no equity dilutionDuring capex period
Credit ratingFresh Brickwork rating, at least triple B minusWithin 45 days
Minority stake conversionShare swap to make Bizotic and Apiqo 100% subsidiariesNext AGM
Payment terms policyNot more than 120 days, targeting 90 daysOngoing

Key Metrics

MetricQ4 FY26
Total income (consolidated)₹50.90 cr, vs ₹48.97 cr in Q4 FY25
Total income FY26₹172.22 cr, +42.98% YoY from ₹120.46 cr in FY25
EBITDA FY26₹47.77 cr, +47.55% YoY
PAT FY26₹29.09 cr, +41.77% YoY
Q4 PBT₹14.44 cr, vs ₹15.49 cr in Q4 FY25
Q4 PAT₹11.07 cr, vs ₹16.65 cr in Q4 FY25
FY27 revenue guidance₹380–400 cr
FY28 revenue expectation₹700–800 cr
Consolidated EBITDA margin guidance24–25%
FY27 EBITDA margin expectation30–35% (with ₹380–400 cr topline)
FY27 PAT expectation₹45 cr conservative, realistically ₹50–55 cr
Consolidated capacity utilization62–65%
Combined installed capacity~1,400–1,600 metric ton per annum
Peak revenue potential (current consolidated capacity)₹450–500 cr
Order book visibility (FY27, consolidated)₹280–300 cr
DMF filings21 filings; 5–6 products in commercial supply to regulated market
Export contribution target (FY27)~60%
Receivable days130–140 days currently; targeting below 180 days by end of FY27
Trade receivables (FY26)~₹100 cr, ~60% of FY26 revenue of ₹170 cr
Outstanding from distributor₹17 cr still outstanding; ₹11 cr recovered
New standalone capex~₹130 cr; funded ₹65–70 cr via term loan, balance from internal accruals
Inventory reduction expected20–25% liquidation by Q2 FY27
Shareholder count~25,000 after split and bonus, up from ~11,000; target 100,000–150,000
Credit ratingBrickwork withdrew at double B minus; fresh rating expected within 45 days, assured at least triple B minus